Cervical pathology

Current Opinion in Obstetrics and Gynecology

Volumn 9, Issue 1, 1997, Pages 57-62

  Herrington, C Simon ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; APOPTOSIS; CELL PROLIFERATION; FEMALE; HUMAN; MESONEPHROMA; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMALL CELL CARCINOMA; TERATOMA; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; WART VIRUS;

EID: 0031003273     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199702000-00013     Document Type: Review

References (54)

1. Kjaer SK, van den Brule AJC, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JMM, Meijer CJLM: Human papillomavirus - the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996, 65:601-606.
2. Herrington CS, Evans MF, Charnock FM, Gray W, McGee JO'D: HPV testing in patients with low-grade cervical cytological abnormalities - a follow-up study. J Clin Pathol 1996, 49:493-496.
3. Jenkins D, Sherlawjohnson C, Gallivan S: Can papillomavirus testing be used to improve cervical cancer screening? Int J Cancer 1996, 65:768-773.
4. Ho GYF, Burk RD, Klein S, Kadish AS, Chan CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87:1365-1371. This study confirms that type-specific HPV persistence, particularly with a high viral load, leads to persistence of CIN lesions rather than regression. This has important implications not only for the natural history of CIN but also for HPV testing.
5. Chua KL, Hjerpe A: Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996, 77:121-127.
6. Fujii T, Tsukazaki K, Kiguchi K, Kubushiro K, Yajima M, Nozawa S: The major E6/E7 transcript of HPV-16 in exfoliated cells from cervical neoplasia patients. Gynecol Oncol 1995, 58:210-215. The majority of attempts to demonstrate potential clinical use of HPV testing have employed the detection of viral DNA. This report describes an approach for the demonstration of transcriptionally active viral infection which therefore reflects viral activity rather than just viral presence. It remains to be determined whether this will be of more clinical value than DNA testing.
7. Rose BR, Thompson CH, Simpson JM, Jarrett CS, Elliott PM, Tattersall HN, Dalrymple C, Cossart YE: Human papillomavirus deoxyribonucleic acid as a prognostic indicator in early-stage cervical cancer: a possible role for type 18. Am J Obstet Gynecol 1995, 173:1461-1468.
8. Abeler VM, Holm R, Nesland JM, Kjorstad KE: Small cell carcinoma of the cervix - a clinipathological study of 26 patients. Cancer 1994, 73:672-677.
9. Fukiwara H, Mitchell MF, Arseneau J, Hale RJ, Wright TC: Clear cell adenosquamous carcinoma of the cervix. Cancer 1996, 76:1591-1600.
10. Hecht JL, Kadish AS, Jiang G, Burk RD: Genetic characterisation of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggest the presence of a sub-type with decreased oncogenic potential, Int J Cancer 1995, 60:369-376. Describes the isolation of two different subtypes of HPV 18 which segregate with squamous lesions of different grade. This has implications not only for the pathobiology of HPV infection but also for HPV typing in clinical practice.
11. Park JS, Chee YH, Mankoong SE, Han SK, Kim TE, Lee HY, Kim SJ: Human papillomavirus detection in cervical carcinoma tissues and para-aortic lymph nodes by the polymerase chain reaction. Gynecol Oncol 1994, 53:344-351.
12. Park JS, Rhyu KS, Kim CJ, Kim HS, Han KT, Ahn HK, Kim SJ, Namkoong SE: Presence of oncogenic HPV DNAs in cervical carcinoma tissues and pelvic lymph nodes associating with proliferating cell nuclear antigen expression. Gynecol Oncol 1996, 60:418-423.
13. Kedzia H, Godzicka-Jozefiak A, Kedzia W, Poreba E: The value of the presence of HPV 16 in pelvic lymph nodes of cervical cancer patients. Eur J Gynaecol Oncol 1996, 16:199-202.
14. Hording U, Ravn V, Knudsen J, Visfeldt J: The use of polymerase chain reaction to detect metastatic cancer cells within lymph nodes in stage I cervical carcinoma. Int J Gynecol Pathol 1995, 14:339-343.
15. Herrington CS: Human papillomaviruses and cervical neoplasia II: interaction with other factors. J Clin Pathol 1995, 48:1-6.
16. Park TW, Richart RM, Sun XW, Wright TC: Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions. J Natl Cancer Inst 1996, 88:355-358. The association of monoclonality of CIN lesions with HPV type has important implications for understanding the biology of the involvement of HPV infection in cervical neoplasia. From a diagnostic point of view, this paper identifies two groups of low-grade lesions: those which are monoclonal and associated with high/intermediate-risk HPV types, and those which are polyclonal and associated with low-risk HPV types. Whether this provides any prognostic information additional to knowledge of HPV type remains to be determined.
17. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV et al.: Prevalence of human papillomavirus in cervical cancer - a worldwide perspective. J Natl Cancer Inst 1995, 87:796-802.
18. Burger MPM, Hollema H, Pieters WJLM, Schroder FP, Quint WGV: Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Br J Cancer 1996, 73:831-836.
19. Borysiewicz LK, Fianderr A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell MEG et al.: A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18 E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523-1527. The author reports a study of the use of a recombinant vaccinia virus for immunization of a small group of patients with advanced cervical carcinoma. Three of eight patients developed HPV-specific antibodies and one developed a cytotoxic T-cell response. These findings are encouraging but larger-scale trials are clearly required.
20. McCluggage WG, Buhidma M, Tang L, Maxwell P, Bharucha H: Monoclonal antibody MIB-1 in the assessment of cervical squamous intraepithelial lesions, Int J Gynecol Pathol 1996, 15:131-136.
21. Resnick M, Lester S, Tate JE, Sheets EE, Sparks C, Crum CP: Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia. Hum Pathol 1996, 27:234-239. A detailed study highlighting correlation of Ki-67 expression with CIN grade rather than HPV type.
22. Al-Saleh W, Delvenne P, Greimers R, Fridman V, Doyen J, Boniver J: Assessment of Ki-67 antigen Immunostaining in squamous intraepithelial lesions of the uterine cervix. Am J Clin Pathol 1995, 104:154-160.
23. Costa MJ: MN and Ki67 (MIB-1) in uterine cervix carcinoma: novel biomarkers with divergent utility. Hum Pathol 1996, 27:217-219.
24. Demeter LM, Stoler MH, Broker TR, Chow LT: Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesions. Hum Pathol 1994, 25:343-348.
25. Herrington CS: Control of HPV replication: implications for squamous neoplasia. J Pathol 1996, 178:237-238.
26. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Muzzioli M, Fabris N, Romanini C, Biagini G: MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol Oncol 1995, 58:28-33.
27. Oka K, Arai T: MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy, Int J Gynecol Pathol 1996, 15:23-27.
28. Saegusa M, Takano Y, Hashimura M, Shoji Y, Okayasu I: The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer 1995, 76:2297-2303.
29. Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I: Correlation of apoptosis with tumour cell differentiation, progression and HPV infection in cervical carcinoma. J Clin Pathol 1996, 49:134-138.
30. Kjaer SK, Brinton LA: Adenocarcinomas of the cervix: the epidemiology of an increasing problem. Epidemiol Rev 1993, 15:486-498.
31. Jackson SR, Hoolingworth TA, Anderson MC, Johnson J, Hammond RH: Glandular lesions of the cervix - cytological and histological correlation. Cytopathology 1996, 7:10-16.
32. Im DD, Duska LR, Rosenshein NB: Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Gynecol Oncol 1995, 59:179-182.
33. Kennedy AW, EITabbakh GH, Biscotti CV, Wirth S: Invasive adenocarcinoma of the cervix following LLETZ for adenocarcinoma in situ. Gynecol Oncol 1995, 58:274-277.
34. Ismail SM: Cone biopsy causes cervical endometriosis and tubo-endometrioid metaplasia. Histopathology 1991, 18:107-114.
35. Al-Nafussi A, Rahilly MR: The prevalence of tubo-endometrial metaplasia and adenomatoid proliferation. Histopathology 1993, 22:177-179.
36. Oliva E, Clement PB, Young RH: Tubal and tubo-endometrioid metaplasia of the uterine cervix. Am J Clin Pathol 1995, 103:618-623. This paper describes refinement of diagnostic criteria for the distinction of metaplastic lesions of the cervix which may be mistaken for malignancy.
37. Daya D, Young RH: Florid deep glands of the uterine cervix: another mimic of adenoma malignum. Am J Clin Pathol 1995, 103:614-617.
38. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Biagini G: Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase staining. Gynecol Oncol 1996, 61:197-203.
39. Bremer GL, Tiebosch ATMG, van der Putten HMHM, de Haan J, Arends JW: Basement membranes in cervical cancer: relationship to pelvic lymph node metastasis and prognosis. Gynecol Oncol 1995, 57:351-355.
40. Biesold C, Kohler U, Horn L-C, Bilek K, Kade R, Emmert C: CD44 exon v6 as a predictor of lymphatic metastases in cervical carcinoma - an immunocytochemical study of 94 cases. Arch Gynaecol Obstet 1995, 256:147-153.
41. Kainz C, Kohlberger P, Sliutz G, Tempfer C, Heinzl H, Reinthaller A, Breitenecker G, Koelbl H: Splice variants of CD44 in human cervical cancer stage lb to llb. Gynecol Oncol 1995, 57:383-387.
42. Hsieh C-Y, Wu C-C, Chen T-M, Chen C-A, Chen C-L, Wang J-F, Chang C-F, Hsieh F-J: Clinical significance of intratumoral blood flow in cervical carcinoma assessed by color Doppler ultrasound. Cancer 1995, 75:2518-2522.
43. Bremer GI, Tiebosch ATMG, van der Putten HWHM, Schouten HJA, de Haan J, Arends JW: Tumor angiogenesis - an independent prognostic parameter in cervical cancer. Am J Obstet Gynecol 1996, 174:126-131.
44. Boyd J, Takahashi H, Waggoner SE, Jones LA, Hajek RA, Wharton JT, Liu F-S, Fukino T, Barrett JC, McLachlan JA: Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilboestrol exposure in utero. Cancer 1996, 77:507-513. A study of clear cell adenocarcinoma showing an association with microsatellite instability rather than mutation of conventional oncogenes. This suggests that this recently described alternative mechanism of carcinogenesis, initially delineated in hereditary non-polyposis-associated colonic carcinoma, may be important in some gynaecological malignancies.
45. Perucho M: Microsatellite instability: the mutator that mutates the other mutator. Nature Medicine 1996, 2:630-631.
46. Hashi A, Yasumizu T, Yoda I, Kou T, Mizuno K, Hirata S, Kato J, Katoh R, Inoue M, Kawaguchi A et al.: A case of small cell carcinoma of the uterine cervix presenting Cushing's syndrome. Gynecol Oncol 1996, 61:427-431.
47. Ishibashiueda H, Imakita M, Yutani C, Ohmichi M, Chiba Y: Small cell carcinoma of the uterine cervix with syndrome of inappropriate antidiuretic syndrome. Mod Pathol 1996, 9:397-400.
48. Albores-Saavedra J, Young RH: Transitional cell neoplasms (carcinomas and inverted papillomas) of the uterine cervix. Am J Surg Pathol 1995, 19:1138-1145.
49. Bell MC, Schnidt-Grimminger D-C, Connor MG, Alvarez RD: A cervical teratoma with invasive squamous cell carcinoma in an HIV-infected patient: a case report Gynecol Oncol 1996, 60:475-479.
50. Layton-Henry J, Scurry J, Planner R, Allen D, Sykes P, Garlands S, Borg A, Tabrizi S: Cervical adenoid basal carcinoma, five cases and literature review, Int J Gynecol Cancer 1996, 6:193-199.
51. Seidman JD, Tavassoli FA: Mesonephric hyperplasia of the uterine cervix: a clinicopathologic study of 51 cases. Int J Gynaecol Pathol 1995, 14:293-299. This paper describes, in detail, the diagnostic criteria and pitfalls in assessing mesonephric cervical lesions. The finding of areas of endometrioid morphology is highlighted and the suggestion made that these represent epididymal differentiation.
52. Clement PB, Young RH, Keh P, Östör AG, Scully RE: Malignant mesonephric neoplasms of the uterine cervix: a report of eight cases, including four with a malignant spindle cell component Am J Surg Pathol 1995, 19:1158-1171.
53. Kurman RJ, Norris HJ, Wilkinson E: Atlas of Tumour Pathology: Tumors of the Cervix, Vagina and Vulva. Washington DC: Armed Forces Institute of Pathology; 1992.
54. Nogales FF: Mesonephric (Wolffian) tumours of the female genital tract: is mesonephric histogenesis a mirage and trap? Curr Diagnostic Pathol 1995, 2:94-100.